CALGARY, Dec. 10 /CNW/ - Novozymes Biologicals Holding A/S announced
today that as of 12:01 a.m. on December 10, 2007, approximately 3,460,335
common shares of Philom have been validly deposited to the Offer by Novozymes
Biologicals Holding A/S, a wholly-owned subsidiary of Novozymes A/S, to
acquire all of the common shares of Philom (including common shares issuable
upon the exercise of any options). Novozymes Biologicals Holding A/S has taken
up these shares, which represent approximately 98% of the common shares of
Philom, and will pay for these shares today by providing the depositary with
sufficient funds for transmittal to the holders of these shares.
Novozymes Biologicals Holding A/S first announced its intention to make
the Offer on October 31, 2007 and it mailed its take-over bid circular to the
shareholders of Philom on November 2, 2007.
Novozymes Biologicals Holding A/S will now exercise its statutory rights
under The Business Corporations Act (Saskatchewan) to compulsorily acquire the
remaining Philom common shares that were not deposited to the Offer. Following
the compulsory acquisition, Novozymes Biologicals Holding A/S intends to cause
Philom to apply to securities regulatory authorities to cease to be a
Novozymes is the world leader in bioinnovation. Together with customers
across a broad array of industries, we create tomorrow's industrial
biosolutions, improving our customers' business and the use of our planet's
resources. Read more at www.novozymes.com.
For further information:
For further information: Press relations: Eva Veileborg Hald, Tel.
(direct): +45 4446 3998, Tel. (mobile): +45 3077 3998; Annegrethe M. Jakobsen,
Tel. (direct): +45 4446 3050, Tel. (mobile): +45 3077 3050; Johan Melchior,
Tel. (direct): +45 4446 0690, Tel. (mobile): +45 3077 0690; Investor & Analyst
relations: Tobias Bjorklund (North America), Tel. (direct): 001 919 494 3483,
Tel. (mobile): 001 919 649 2565; Camilla Kinch Jensen, Tel. (direct): +45 4446
0852, Tel. (mobile): +45 3077 0852; Ian Christensen, Tel. (direct): +45 4446
0341, Tel. (mobile): +45 3077 0341